Baijin Life Science Holdings Limited (1466) announced that, based on the preliminary assessment of its unaudited consolidated management accounts, the Group is expected to record a net profit of approximately HK$2.5 million for the six months ended 30 September 2025. This figure compares with a net loss of about HK$1.9 million for the same period in 2024.

The increase in performance is primarily attributed to the gain on the change in fair value of a convertible bond, which more than offset a decrease in gross profit. As the interim results are not yet finalized, the information should be regarded as a preliminary indication. The official interim results announcement is scheduled for publication on 27 November 2025.

Shareholders and potential investors are advised to exercise caution when dealing in the Company’s securities.